Radiopharmaceuticals for prostate cancer to go nuclear with $6.3 bn in sales by 2030 GlobalData Sep 18, 2024 GlobalData analyst consensus forecast predicts the global revenue of Pluvicto to rise from $980 million in 2023 to $4.3 billion by…
